International Stem Cell (OTCMKTS:ISCO – Get Free Report) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.03) EPS for the quarter, Zacks reports. The business had revenue of $2.32 million for the quarter.
International Stem Cell Price Performance
ISCO stock remained flat at $0.18 during mid-day trading on Friday. 84 shares of the company’s stock traded hands, compared to its average volume of 1,816. The company has a market capitalization of $1.42 million, a P/E ratio of -2.95 and a beta of 0.06. International Stem Cell has a 1-year low of $0.11 and a 1-year high of $0.27. The firm’s 50-day moving average price is $0.16 and its 200-day moving average price is $0.15.
International Stem Cell Company Profile
International Stem Cell Corporation (OTCMKTS:ISCO) is a biotechnology company focused on the development and commercialization of human parthenogenetic stem cells (hpSC) for therapeutic and research applications. Parthenogenetic stem cells are derived from unfertilized human eggs and offer a scalable, ethically noncontroversial source of pluripotent cells. ISCO’s proprietary hpSC lines can be directed to differentiate into a wide variety of cell types, enabling preclinical programs in areas such as neurodegenerative disease, liver disease, diabetes and corneal regeneration.
In addition to its therapeutic pipeline, International Stem Cell maintains a research products division that supplies hpSC lines, differentiated cell populations and media formulations to academic institutions, biotechnology companies and contract research organizations.
Read More
- Five stocks we like better than International Stem Cell
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Receive News & Ratings for International Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for International Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.
